Glenn, a 25+ year veteran of the software industry, has been instrumental in the building of several successful software companies, co-founded Syapse in 2008. Early in his career he spent many years selling and supporting data management and collaboration software into highly regulated industries including healthcare. He was also a co-founder and Chief Operating Officer of NetIQ, a leading supplier of security, system management, and web analytics software, leading them from initial product launch in 1996 to IPO in 1999 to $300 million in annual revenue in 2003. In addition to Glenn’s role at Syapse, he stays abreast of modern technology trends as an investor and/or advisor to leading cloud, SaaS, and collaboration software companies including Puppet Labs, Cloud Sherpas and SchoolMessenger and is a member of UCSF Med Center’s Technology Advisory Group. Glenn received a B.S. in Business Administration and Marketing from the University of Illinois at Urbana-Champaign, and is a frequent guest lecturer, mentor and advisor at both the University of Illinois and Stanford University.
Jonathan Hirsch is the Founder and President of Syapse, a software company transforming healthcare by bringing omics into routine medical use. At Syapse, Jonathan works closely with diagnostic and healthcare providers, helping translate customer problems into software solutions. Jonathan is an Advisory Board member of the SXSW Accelerator, a mentor for UCSF Lean Launchpad for Healthcare course, and a member of the Steering Committee of Free the Data!, an effort started by Genetic Alliance to crowdsource the interpretation of cancer genes. Earlier in his career, Jonathan worked in Neuroscience Commercial Development at Abbott Laboratories, where he developed strategies to fund drug development through partnerships and private equity financing. His research at the Center for Molecular Neurobiology at the University of Chicago helped establish the effect of exercise on promoting hippocampal neurogenesis and combating Alzheimer’s disease. Jonathan received an M.Sci. in Neuroscience from Stanford University, and an A.B. in Biology and Political Philosophy from the University of Chicago.
Tony has been applying knowledge representation and reasoning technologies to biomedical and web applications since 1996. Prior to co-founding Syapse, Tony's experience with biological data included six years at Ingenuity Systems, where he was responsible for the architecture of the software and structured content. After Ingenuity, Tony was Vice President of Engineering at Tumri, applying semantic technologies to targeted internet advertising. Tony received an M.S. in Computer Science and Ph.D. in Physics from Stanford University, and an A.B. in Physics and Mathematics from Harvard University.
With a proven track record of seven successful startups including two IPOs in the past 20 years, Palmer has specialized in accelerating the foundation and growth of early-stage companies that span enterprise software, the Internet, ecommerce, and biotech. Palmer was co-founder and founding CEO of Vertica Systems (acquired by HP). Prior to Vertica, Palmer was the senior vice president of operations and CIO for Infinity Pharmaceuticals (NASDAQ: INFI) and has held executive positions at Bowstreet (acquired by IBM), pcOrder.com and Trilogy.
Peter Donnelly is director of the Wellcome Trust Centre for Human Genetics and professor of statistical science at the University of Oxford. His current research focuses on understanding the genetic basis of common human diseases, human demographic history, bacterial evolution and infection, and the mechanisms involved in mammalian recombination. Donnelly played a major role in the HapMap project, and he currently chairs the Wellcome Trust Case Control Consortium (WTCCC) and its successor, WTCCC2, a large international collaboration studying the genetic basis of more than 20 common human diseases and conditions in over 60,000 people. He also leads WGS500, an Oxford collaboration with Illumina to sequence 500 individuals with a range of clinical conditions, to assess the short-term potential for whole-genome sequencing in clinical medicine.
Scott Barclay is a digital health innovator and strategist based in Palo Alto, CA focused on new applications that leverage big data and new forms of communication to both evolve and disrupt the ecosystem's current approach to care. Scott holds or has recently held advisory roles or completed strategic projects with GE Healthymagination, Accenture global digital health labs, Medgle, AgeTak, Doximity, HealthTap, QualcommLife, and Stanford's StartX incubator.
Dave has more than 18 years of leadership experience in delivering enterprise class software and content solutions in life sciences and medicine. Previously he was CTO at WellnessFX and oversaw the development of the visualized personal health dashboard and companion mobile app. Formerly, he was CTO at Tethys, leading commercial operations and information functions in diagnosing those most at risk of developing Type 2 Diabetes. Prior, he built very, very large databases at Roche, Pfizer and Incyte that created clinical trial candidates from data mining, influenza resistance trends in real time, and toxicology guidance from text analytics... David advises a number of Bay Area startups and non-profit foundations.
Dr. Webb joined Celgene - San Diego in September, 2003 as Vice President, Research and retired in June, 2011. Between 1995 and 2003, he held executive management positions in Syrrx, OSI Pharmaceuticals, Cadus Pharmaceutical Corporation, Axiom Biotechnologies, Inc., and Syntex, Inc., developing and leading drug discovery programs focused on inflammation, asthma, cancer and diabetes. Prior to his experience in the biotechnology industry, Dr. Webb was a member of the Department of Cell Biology at the Roche Institute of Molecular Biology from 1973 to 1987 and Adjunct Professor of Human Genetics at Columbia University College of Physicians and Surgeons. He has published over 200 peer-reviewed publications and abstracts and has served on numerous editorial boards in the field of immunology. Dr. Webb received his Ph.D. from Rutgers University and was a Dernham Junior Fellow in Cancer Research at UCSF before joining the Roche Institute.
Mark has worked on biomedical terminology projects for more than 25 years beginning at the University of California San Francisco (UCSF), where he became the lead extramural architect for the National Library of Medicine (NLM) Unified Medical Language System (UMLS) Metathesaurus. While teaching in the computer science department at UC Berkeley, Mark co-founded Apelon, a pioneer in biomedical terminology projects at the National Cancer Institute, Veterans Administration, Department of Defense, and Health and Human Services. Mark is currently Director of Interoperability at eHealthTrust, and is on the staff of the Center for Bioinformatics at the Mount Sinai School of Medicine. Mark has undergraduate and graduate degrees from Dartmouth, and studied in the Ph.D. program in Computer Science at Harvard.